The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J05 | Antivirals for systemic use | |
| 3 | J05A | Direct acting antivirals | |
| 4 | J05AR | Antivirals for treatment of HIV infections, combinations | |
| 5 | J05AR08 | Emtricitabine, tenofovir disoproxil and rilpivirine |
| Active Ingredient | Description | |
|---|---|---|
| Emtricitabine, Tenofovir disoproxil and Rilpivirine |
Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate. Both emtricitabine and tenofovir have activity that is specific to HIV-1, HIV-2 and, HBV. Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EVIPLERA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
